Autolus Therapeutics (NASDAQ:AUTL) Price Target Cut to $10.00 by Analysts at Mizuho

Autolus Therapeutics (NASDAQ:AUTL) had its target price lowered by Mizuho from $12.00 to $10.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages also recently commented on AUTL. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Friday, March 27th. HC Wainwright started coverage on shares of Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective for the company. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.50.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL opened at $1.38 on Tuesday. The stock has a market capitalization of $367.27 million, a P/E ratio of -1.28 and a beta of 1.95. The business has a 50-day moving average of $1.48 and a two-hundred day moving average of $1.52. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%. The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $23.92 million. As a group, research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of the business. Marex Group plc acquired a new stake in shares of Autolus Therapeutics in the second quarter worth $28,000. Independent Advisor Alliance acquired a new position in Autolus Therapeutics during the 4th quarter valued at $28,000. SmartHarvest Portfolios LLC bought a new stake in Autolus Therapeutics in the 4th quarter valued at $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in Autolus Therapeutics in the 3rd quarter worth $46,000. Finally, R Squared Ltd increased its holdings in shares of Autolus Therapeutics by 40.1% during the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after purchasing an additional 8,730 shares during the period. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.